Edition:
United States

Alere Inc (ALR)

ALR on New York Consolidated

48.86USD
25 May 2017
Change (% chg)

-- (--)
Prev Close
$48.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,345,558
52-wk High
$49.53
52-wk Low
$31.47

ALR

Chart for ALR

About

Alere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals... (more)

Overall

Beta: 0.22
Market Cap(Mil.): $4,250.95
Shares Outstanding(Mil.): 87.00
Dividend: --
Yield (%): --

Financials

  ALR Industry Sector
P/E (TTM): -- 44.47 17.43
EPS (TTM): -1.86 -- --
ROI: -3.75 8.90 -5.41
ROE: -9.88 13.88 -4.69

BRIEF-Greenlight Capital takes share stake in Alere, Micron Technology

* Greenlight Capital Inc takes share stake of 1.0 million shares in Alere Inc

May 15 2017

BRIEF-Alere Inc files for non-timely 10-Q

* Alere Inc says does not anticipate significant changes in results of operations for quarter ended march 31, 2017 versus quarter ended march 31, 2016

May 11 2017

BRIEF-Alere Inc modifies consent solicitations for notes

* Alere Inc. Announces modifications of consent solicitations for Alere Inc.'s notes

May 04 2017

BRIEF-Alere reports commencement of consent solicitations for notes

* Alere Inc. Announces commencement of consent solicitations for alere inc.'s notes

May 01 2017

BRIEF-Alere launches the first-ever rapid test to screen malaria infection in asymptomatic individuals

* Alere launches the Alere malaria AG P.F, the first-ever rapid test to screen malaria infection in asymptomatic individuals Source text for Eikon: Further company coverage:

Apr 25 2017

BRIEF-Alere Inc enters into third amendment

* Alere Inc - on April 24, co entered into third amendment, dated as of April 24, to secured credit agreement, dated as of June 18, 2015

Apr 24 2017

Abbott sees Alere as challenging 'fixer-upper' after revised deal

Abbott Laboratories said it was looking to close the recently revised deal to buy Alere Inc in the coming months, calling the diagnostics company "a bit of a fixer-upper".

Apr 19 2017

UPDATE 3-Abbott sees Alere as challenging "fixer-upper" after revised deal

* Closing of new Alere deal is a little unpredictable - CFO (Adds conference call details; Updates shares)

Apr 19 2017

BRIEF-Abbott CFO says "We're not going to really be in a good position to give a lot of detailed guidance (on Alere) until minimum Q4" - Conf Call

* Abbott CEO says "the acquisition of Alere will significantly expand our diagnostics presence and leadership in that space" - Conf Call

Apr 19 2017

BRIEF-Alere concluded its financial statements as of Dec 31, 2015 and 2014 should not be relied upon

* Alere - On April 12, concluded co's financial statements and other financial data as of December 31, 2015 and 2014 should not be relied upon - SEC filing

Apr 17 2017

More From Around the Web

Earnings vs. Estimates